000282536 001__ 282536
000282536 005__ 20251201103218.0
000282536 0247_ $$2doi$$a10.1111/ene.70453
000282536 0247_ $$2ISSN$$a1351-5101
000282536 0247_ $$2ISSN$$a1468-1331
000282536 037__ $$aDZNE-2025-01299
000282536 041__ $$aEnglish
000282536 082__ $$a610
000282536 1001_ $$aVieregge, Magdalena$$b0
000282536 245__ $$aDermal Alpha‐Synuclein Aggregation in Seed Amplification Assays for Parkinson's Disease Subtype Differentiation
000282536 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
000282536 3367_ $$2DRIVER$$aarticle
000282536 3367_ $$2DataCite$$aOutput Types/Journal article
000282536 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764579693_18435
000282536 3367_ $$2BibTeX$$aARTICLE
000282536 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282536 3367_ $$00$$2EndNote$$aJournal Article
000282536 520__ $$aBackgroundSkin biopsies and seed amplification assays (SAA) provide a sensitive and potentially quantitative method to detect alpha-synuclein (a-syn) aggregation in peripheral nerve fibers in Parkinson's disease (PD). Relating to the previously published hypothesis that PD may either originate in the peripheral (body-first) or central (brain-first) nervous system, we investigated whether patients with clinical features that have been reported to be associated with a suspected body-first subtype of PD exhibit higher levels of a-syn aggregation in dermal nerve fibers compared to those without these features. Patients with isolated REM sleep behavior disorder (iRBD) representing a suspected premotor stage of body-first PD were studied in comparison to the PD cohort.MethodsPatients were categorized on the basis of clinical features, and SAA parameters such as lag time, number of positive curves, and titers were analyzed and correlated with clinical features.ResultsAlthough patients with clinical features of suspected body-first PD showed slightly higher titers, significant differences were mainly observed between iRBD patients and PD patients.ConclusionsOur data suggest that widespread α-syn aggregation in advanced PD limits the use of SAA in skin biopsies for subtype differentiation.
000282536 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282536 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000282536 7001_ $$aKuzkina, Anastasia$$b1
000282536 7001_ $$aJanzen, Annette$$b2
000282536 7001_ $$aOertel, Wolfgang H.$$b3
000282536 7001_ $$0P:(DE-2719)9003277$$aSommerauer, Michael$$b4$$udzne
000282536 7001_ $$aVolkmann, Jens$$b5
000282536 7001_ $$00000-0003-2883-0009$$aDoppler, Kathrin$$b6
000282536 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.70453$$gVol. 32, no. 12, p. e70453$$n12$$pe70453$$tEuropean journal of neurology$$v32$$x1351-5101$$y2025
000282536 8564_ $$uhttps://pub.dzne.de/record/282536/files/DZNE-2025-01299.pdf$$yOpenAccess
000282536 8564_ $$uhttps://pub.dzne.de/record/282536/files/DZNE-2025-01299.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000282536 909CO $$ooai:pub.dzne.de:282536$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000282536 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003277$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000282536 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282536 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2022$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-12$$wger
000282536 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
000282536 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000282536 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000282536 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NEUROL : 2022$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-12
000282536 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
000282536 9201_ $$0I:(DE-2719)1013020$$kAG Petzold$$lVascular Neurology$$x0
000282536 980__ $$ajournal
000282536 980__ $$aVDB
000282536 980__ $$aUNRESTRICTED
000282536 980__ $$aI:(DE-2719)1013020
000282536 9801_ $$aFullTexts